On January 14th, a grand opening ceremony and investment promotion conference was held in the National Bio-Industry Base of Pingshan New District, Shenzhen. The Shenzhen Biomedical Innovation Industrial Park with a total investment of 693 million yuan was officially put into use. In addition to providing factories that can meet GMP standards certification, the park will also create five service platforms: policy support, investment and financing, human resources, industrialization, and business platforms. According to forecasts, the output value of the bio-industry in Pingshan New District will reach 20 billion yuan this year. In 2005, Shenzhen was recognized as the first batch of national bio-industry bases by the National Development and Reform Commission, and Shenzhen bio-industry was included in the overall development of the country. In 2008, Shenzhen's bio-industry sales revenue was 35.85 billion yuan, and the industrial scale entered the top three cities in the national bio-industry base. In 2012, the income of Shenzhen's bio-industry reached 91 billion yuan. In July last year, relevant personnel of the Shenzhen Development and Reform Commission revealed that in 2013, the scale of Shenzhen's bio-industry exceeded RMB 100 billion for the first time, which was higher than GDP growth. The bio-industry report provided by the Shenzhen Science and Technology Innovation Committee to reporters recently showed that the scale of the bio-industry in Shenzhen last year is expected to be 160 billion yuan. Now, in the bio-medical, bio-medicine, bio-agriculture, bio-environmental protection, bio-energy, bio-manufacturing and other fields, bio-industry, "Shenzhen advantage" has been highlighted. There is no rural “plant city†In September last year, the first national seed industry innovation fund with social capital investment as the main body was established in Qianhai, Shenzhen. The fund is composed of 118 national agricultural science and technology park alliance funds, seed industry listed companies, local government and social funds actively participate in the "1 + 3" investment model, the park's parent fund first phase has raised 515 million yuan, for the Shenzhen species Industry construction provides financial support. In fact, in the basic research of biological breeding, technology application research and industrial demonstration and promotion, Shenzhen has formed a relatively complete industrial chain. Many people are asking, how can there be such an emerging force in biological breeding in Shenzhen, which has no rural areas, no farmer system, and only 100,000 mu of agricultural land? In 2010, Shenzhen launched the National Agricultural Science and Technology Park and the Modern Agricultural Biological Breeding Innovation Demonstration Zone with biological breeding as the core content, and the research experimental land area reached 7,835 mu. Seven biological breeding science and technology parks have been built with priority in the National Agricultural Science and Technology Park. The phoenix tree came to the phoenix. “In biological breeding, we have successfully introduced nine innovative teamsâ€. Relevant personnel of the Shenzhen Science and Technology Innovation Committee told reporters that innovative teams such as crop molecular design breeding, super hybrid rice, Huada gene, and bio-solar, led by domestic and international authorities Deng Xingwang, Yuan Longping, Yang Huanming, and Zhang Shuguang, have settled in Shenzhen. In 2011, the Chinese Academy of Agricultural Sciences and Huada Gene achieved cooperation and established the Shenzhen Institute of Biological Breeding Innovation of the Chinese Academy of Agricultural Sciences. The reporter learned that as of October 2014, Shenzhen has built 31 national, provincial and municipal key laboratories, engineering laboratories, engineering center technology centers and other agricultural innovation carriers. Among them, 1 national key laboratory, 2 provincial key laboratories, 11 municipal key laboratories, 6 engineering centers, 8 engineering laboratories and 3 public technology service platforms were established. The enhancement of agricultural biological research strength has greatly promoted the development of Shenzhen's agricultural biotechnology industry, and has led a number of agricultural organisms such as Shenzhen Batian Ecological Engineering Co., Ltd., Shenzhen Agricultural Science Group, and Shenzhen Jinxinong Feed Co., Ltd. Technology companies are doing their jobs. "Shenzhen First" in the biological industry In 2012, Shenzhen Kangtai Biological Products Co., Ltd. listed the world's first hepatitis B vaccine for “low unresponsive people†and achieved great market response. The largest hepatitis B vaccine production company in China has a market share of more than 50%, and more than 300 million Chinese have been vaccinated with Kangtai recombinant hepatitis B vaccine. Today, Shenzhen has maintained many firsts in the independent innovation of the bio-industry: it has produced the world's first new gene therapy drug, the first Asian gene map, the first bio-engineering drug in China, the first A large number of independent innovations such as medical nuclear magnetic resonance diagnostic apparatus, the first color ultrasound Doppler blood imaging system (color ultrasound), the first gamma ray treatment system, and the first automatic biochemical analyzer. Shandong Longze Mechanical Equipment Co.,Ltd , https://www.pelletmachinefactory.com